MacroGenics (NASDAQ:MGNX) will be issuing its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $2.62 per share for the quarter.
MacroGenics (NASDAQ MGNX) opened at $23.30 on Monday. MacroGenics has a 1-year low of $14.36 and a 1-year high of $24.26. The company has a market cap of $857.97, a price-to-earnings ratio of -5.19 and a beta of 2.79.
In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Eric Blasius Risser sold 3,000 shares of the company’s stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the sale, the senior vice president now directly owns 12,100 shares in the company, valued at $272,250. The disclosure for this sale can be found here. Insiders sold a total of 13,000 shares of company stock worth $267,500 over the last ninety days. Insiders own 8.30% of the company’s stock.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.